{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:05:32Z","timestamp":1792515932319,"version":"4.5.0"},"reference-count":53,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Centre, Poland","award":["2017\/25\/B\/NZ7\/01048"],"award-info":[{"award-number":["2017\/25\/B\/NZ7\/01048"]}]},{"name":"National Science Centre, Poland","award":["N42\/DBS\/000328"],"award-info":[{"award-number":["N42\/DBS\/000328"]}]},{"name":"National Science Centre, Poland","award":["N42\/DBS\/000416"],"award-info":[{"award-number":["N42\/DBS\/000416"]}]},{"name":"Jagiellonian University Medical College in Krak\u00f3w, Poland","award":["2017\/25\/B\/NZ7\/01048"],"award-info":[{"award-number":["2017\/25\/B\/NZ7\/01048"]}]},{"name":"Jagiellonian University Medical College in Krak\u00f3w, Poland","award":["N42\/DBS\/000328"],"award-info":[{"award-number":["N42\/DBS\/000328"]}]},{"name":"Jagiellonian University Medical College in Krak\u00f3w, Poland","award":["N42\/DBS\/000416"],"award-info":[{"award-number":["N42\/DBS\/000416"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: To address the unmet clinical needs in the treatment of epilepsy and pain, the continued development of more effective and safer anticonvulsants and analgesics is still necessary. Therefore, herein we report synthesis and antiseizure\/antinociceptive evaluation of a focused series of 3-(benzo[b]thiophen-2-yl)pyrrolidine-2,5-dione derivatives. Methods: The anticonvulsant properties were investigated in acute models of seizures, namely the maximal electroshock (MES), the 6 Hz (32 mA), and subcutaneous pentylenetetrazole (scPTZ) seizure models, whereas analgesic activity was tested in the model of a tonic pain\/formalin test and oxaliplatin-induced neuropathic pain (in CD-1-mice, i.p.). In addition, a number of in vitro assays were performed, aiming at the evaluation of the drug-like properties of the compounds disclosed herein. Results: We identified 33 as a lead compound with the most promising antiseizure properties, i.e., ED50 (MES) = 27.4 mg\/kg and ED50 (6 Hz, 32 mA) = 30.8 mg\/kg. Furthermore, 33 at a dose of 100 mg\/kg significantly prolonged the latency time to the first seizure episode in the scPTZ model and at high doses did not impaire coordination of mice in the rotarod test (TD50 &gt; 200 mg\/kg). Apart from broad antiseizure protection, 33 demonstrated a significant analgesic effect in the formalin test (45 mg\/kg, i.p.), and effectively alleviated allodynia in the oxaliplatin-induced neuropathic pain model (30 and 45 mg\/kg). The binding assays suggest that the most plausible mechanism of action relies on interaction with the neuronal voltage-sensitive sodium channel (site 2). Furthermore, the drug-like potential of 33 supports favorable in vitro results, i.e., no hepatocytotoxicity and neurocytotoxicity at a high concentration of 100 \u03bcM, as well as a lack of mutagenicity at a concentration as high as 500 \u03bcM. Conclusions: Compound 33 identified in the current studies is proposed to be an interesting candidate for further preclinical development as therapy for epilepsy and neuropathic pain.<\/jats:p>","DOI":"10.3390\/ph17111532","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T04:47:17Z","timestamp":1731646037000},"page":"1532","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Discovery of New 3-(Benzo[b]Thiophen-2-yl)Pyrrolidine-2,5-Dione Derivatives as Potent Antiseizure and Antinociceptive Agents\u2014In Vitro and In Vivo Evaluation"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0190-1682","authenticated-orcid":false,"given":"Anna","family":"Rapacz","sequence":"first","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-3825","authenticated-orcid":false,"given":"Marcin","family":"Jakubiec","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Abram","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jasi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Chrzan","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"G\u00f3ra","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6377-5749","authenticated-orcid":false,"given":"Anna","family":"Dziubina","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2477-5607","authenticated-orcid":false,"given":"Katarzyna","family":"W\u00f3jcik-Pszczo\u0142a","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-224X","authenticated-orcid":false,"given":"Paulina","family":"Koczurkiewicz-Adamczyk","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Ciepiela","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1260-4253","authenticated-orcid":false,"given":"El\u017cbieta","family":"P\u0119kala","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Obniska","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-371X","authenticated-orcid":false,"given":"Krzysztof","family":"Kami\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in Adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","article-title":"New Epilepsy Therapies in Development","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tang, F., Hartz, A.M.S., and Bauer, B. (2017). Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. Front. Neurol., 8.","DOI":"10.3389\/fneur.2017.00301"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/8336561","article-title":"Managing Chronic Neuropathic Pain: Recent Advances and New Challenges","volume":"2022","author":"Hange","year":"2022","journal-title":"Neurol. Res. Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic Pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","article-title":"Antidepressants and Gabapentinoids in Neuropathic Pain: Mechanistic Insights","volume":"338","author":"Kremer","year":"2016","journal-title":"Neuroscience"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/ccr3.3143","article-title":"Paroxysmal Pain as the Only Presentation of Focal Epilepsy","volume":"8","author":"Garcez","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1528-1157.1999.tb00790.x","article-title":"Localized Pain Associated with Seizures Originating in the Parietal Lobe","volume":"40","author":"Siegel","year":"1999","journal-title":"Epilepsia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","article-title":"Antiepileptic Drugs in Non-Epilepsy Disorders","volume":"22","author":"Landmark","year":"2008","journal-title":"CNS Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"L\u00f6scher, W. (2021). Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs with Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.730257"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Pei, J., and Lai, L. (2020). LigBuilder V3: A Multi-Target de Novo Drug Design Approach. Front. Chem., 8.","DOI":"10.3389\/fchem.2020.00142"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"G\u00f3ra, M., Czopek, A., Rapacz, A., Dziubina, A., G\u0142uch-Lutwin, M., Mordyl, B., and Obniska, J. (2020). Synthesis, Anticonvulsant and Antinociceptive Activity of New Hybrid Compounds: Derivatives of 3-(3-Methylthiophen-2-Yl)-Pyrrolidine-2,5-Dione. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165750"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","article-title":"Design, Synthesis, and Anticonvulsant Activity of New Hybrid Compounds Derived from 2-(2,5-Dioxopyrrolidin-1-Yl)Propanamides and 2-(2,5-Dioxopyrrolidin-1-Yl)Butanamides","volume":"58","author":"Zagaja","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1021\/acs.jmedchem.7b01114","article-title":"Multifunctional Hybrid Compounds Derived from 2-(2,5-Dioxopyrrolidin-1-Yl)-3-Methoxypropanamides with Anticonvulsant and Antinociceptive Properties","volume":"60","author":"Abram","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2016.04.033","article-title":"Anticonvulsant and Antinociceptive Activity of New Amides Derived from 3-Phenyl-2,5-Dioxo-Pyrrolidine-1-Yl-Acetic Acid in Mice","volume":"781","author":"Rapacz","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Abram, M., Jakubiec, M., Rapacz, A., Mogilski, S., Latacz, G., Kami\u0144ski, R.M., and Kami\u0144ski, K. (2020). The Search for New Anticonvulsants in a Group of (2,5-Dioxopyrrolidin-1-Yl)(Phenyl)Acetamides with Hybrid Structure\u2014Synthesis and In Vivo\/In Vitro Studies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228780"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.ejmech.2008.05.020","article-title":"Synthesis and Anticonvulsant Activity of New N-[(4-Arylpiperazin-1-Yl)-Alkyl] Derivatives of 3-Phenyl-Pyrrolidine-2,5-Dione","volume":"44","author":"Obniska","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ardp.200900250","article-title":"Synthesis and Anticonvulsant Properties of New Mannich Bases Derived from 3-Aryl-Pyrrolidine-2,5-Diones. Part 1","volume":"343","author":"Obniska","year":"2010","journal-title":"Arch. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1021\/ja9608306","article-title":"An Improved Catalyst System for Aromatic Carbon\u2212Nitrogen Bond Formation:\u2009 The Possible Involvement of Bis(Phosphine) Palladium Complexes as Key Intermediates","volume":"118","author":"Wolfe","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the Chemical Beauty of Drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Daina, A., Michielin, O., and Zoete, V. (2017). SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. Sci. Rep., 7.","DOI":"10.1038\/srep42717"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_23","first-page":"99","article-title":"Simplified Method of Evaluating Dose-Effect Experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.28.4.325","article-title":"Specific Antagonism of GABA-Mediated Postsynaptic Inhibition in Cultured Mammalian Spinal Cord Neurons","volume":"28","author":"Macdonald","year":"1978","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dantas, L.L.S.F.R., Fonseca, A.G., Pereira, J.R., Furtado, A.A., Gomes, P.a.T.M., Fernandes-Pedrosa, M.F., Leite, A.C.L., R\u00eago, M.J.B.M., Pitta, M.G.R., and Lemos, T.M.a.M. (2020). Anti-Inflammatory and Antinociceptive Effects of the Isatin Derivative (Z)-2-(5-Chloro-2-Oxoindolin-3-Ylidene)-N-Phenyl-Hydrazinecarbothioamide in Mice. Braz. J. Med. Biol. Res., 53.","DOI":"10.1590\/1414-431x202010204"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.12688\/f1000research.18338.1","article-title":"A Refinement to the Formalin Test in Mice","volume":"8","author":"Lopes","year":"2019","journal-title":"F1000Res"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of Antiepileptic Drugs Tiagabine, Lamotrigine, and Gabapentin in Mouse Models of Acute, Prolonged, and Chronic Nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nguyen, T., Chen, X., Chai, J., Li, R., Han, X., Chen, X., Liu, S., Chen, M., and Xu, X. (2020). Antipyretic, Anti-Inflammatory and Analgesic Activities of Periplaneta americana Extract and Underlying Mechanisms. Biomed. Pharmacother., 123.","DOI":"10.1016\/j.biopha.2019.109753"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2017.01.018","article-title":"Formalin Injection Produces Long-Lasting Hypersensitivity with Characteristics of Neuropathic Pain","volume":"797","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2006.04.009","article-title":"Antinociceptive Efficacy of Lacosamide in a Rat Model for Painful Diabetic Neuropathy","volume":"539","author":"Beyreuther","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/WCO.0000000000000980","article-title":"Advances in the Treatment of Neuropathic Pain","volume":"34","author":"Attal","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eplepsyres.2018.03.024","article-title":"Evaluation of Anticonvulsant and Analgesic Activity of New Hybrid Compounds Derived from N-Phenyl-2-(2,5-Dioxopyrrolidin-1-Yl)-Propanamides and -Butanamides","volume":"143","author":"Rapacz","year":"2018","journal-title":"Epilepsy Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2017.12.036","article-title":"Antiallodynic and Antihyperalgesic Activity of New 3,3-Diphenyl-Propionamides with Anticonvulsant Activity in Models of Pain in Mice","volume":"821","author":"Rapacz","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"a022814","DOI":"10.1101\/cshperspect.a022814","article-title":"Role of Sodium Channels in Epilepsy","volume":"6","author":"Kaplan","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737175.2016.1121097","article-title":"The Possible Use of the L-Type Calcium Channel Antagonist Verapamil in Drug-Resistant Epilepsy","volume":"16","author":"Nicita","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.neuropharm.2003.11.028","article-title":"Nifedipine Affects the Anticonvulsant Activity of Topiramate in Various Animal Models of Epilepsy","volume":"46","author":"Russo","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-Gated Sodium Channels as Therapeutic Targets in Epilepsy and Other Neurological Disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Barbieri, R., Nizzari, M., Zanardi, I., Pusch, M., and Gavazzo, P. (2023). Voltage-Gated Sodium Channel Dysfunctions in Neurological Disorders. Life, 13.","DOI":"10.3390\/life13051191"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/13543784.2020.1728254","article-title":"Neuropathic Pain: Preclinical and Early Clinical Progress with Voltage-Gated Sodium Channel Blockers","volume":"29","author":"Kushnarev","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and Antihyperalgesic Activity of 3-[4-(3-Trifluoromethyl-Phenyl)-Piperazin-1-Yl]-Dihydrofuran-2-One Compared to Pregabalin in Chemotherapy-Induced Neuropathic Pain in Mice","volume":"122","author":"Cios","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","article-title":"The Role of Technical, Biological and Pharmacological Factors in the Laboratory Evaluation of Anticonvulsant Drugs. II. Maximal Electroshock Seizure Models","volume":"8","author":"Fassbender","year":"1991","journal-title":"Epilepsy Res."},{"key":"ref_42","first-page":"273","article-title":"Comparative Assay of Antiepileptic Drugs by \u201cPsychomotor\u201d Seizure Test and Minimal Electroshock Threshold Test","volume":"107","author":"Brown","year":"1953","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological Characterization of the 6 Hz Psychomotor Seizure Model of Partial Epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/epi.12893","article-title":"Genetic Background of Mice Strongly Influences Treatment Resistance in the 6 Hz Seizure Model","volume":"56","author":"Leclercq","year":"2015","journal-title":"Epilepsia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00702-014-1173-7","article-title":"Effects of WIN 55,212-2 (a Non-Selective Cannabinoid CB1 and CB2 Receptor Agonist) on the Protective Action of Various Classical Antiepileptic Drugs in the Mouse 6 Hz Psychomotor Seizure Model","volume":"121","author":"Wlaz","year":"2014","journal-title":"J. Neural Transm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pbb.2003.09.019","article-title":"Comparative Anticonvulsant Activity of N-Acetyl-1-Aryl-6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinoline Derivatives in Rodents","volume":"77","author":"Ferreri","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s43440-019-00037-6","article-title":"Long-Term Vigabatrin Treatment Modifies Pentylenetetrazole-Induced Seizures in Mice: Focused on GABA Brain Concentration","volume":"72","author":"Zakrocka","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2018.03.009","article-title":"Pharmacological Characterization of the Cannabinoid Receptor 2 Agonist, \u03b2-Caryophyllene on Seizure Models in Mice","volume":"57","author":"Tchekalarova","year":"2018","journal-title":"Seizure"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0920-1211(91)90041-D","article-title":"The Role of Technical, Biological and Pharmacological Factors in the Laboratory Evaluation of Anticonvulsant Drugs. IV. Protective Indices","volume":"9","author":"Nolting","year":"1991","journal-title":"Epilepsy Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/em.21677","article-title":"International Round-Robin Study on the Ames Fluctuation Test","volume":"53","author":"Reifferscheid","year":"2012","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Koczurkiewicz-Adamczyk, P., Kla\u015b, K., Gunia-Krzy\u017cak, A., Piska, K., Andrysiak, K., St\u0119pniewski, J., Lasota, S., W\u00f3jcik-Pszczo\u0142a, K., Dulak, J., and Madeja, Z. (2021). Cinnamic Acid Derivatives as Cardioprotective Agents against Oxidative and Structural Damage Induced by Doxorubicin. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126217"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1523\/JNEUROSCI.06-07-02064.1986","article-title":"3H-Batrachotoxinin-A Benzoate Binding to Voltage-Sensitive Sodium Channels: Inhibition by the Channel Blockers Tetrodotoxin and Saxitoxin","volume":"6","author":"Brown","year":"1986","journal-title":"J. Neurosci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1073\/pnas.79.11.3656","article-title":"[3H]Nitrendipine-Labeled Calcium Channels Discriminate Inorganic Calcium Agonists and Antagonists","volume":"79","author":"Gould","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1532\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:32:49Z","timestamp":1760113969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/11\/1532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ph17111532"],"URL":"https:\/\/doi.org\/10.3390\/ph17111532","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}